Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)

Ocular Therapeutix's Operating Leases history runs 8 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Operating Leases fell 13.07% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 13.07% YoY), while the FY2025 annual figure was $2.8 million, down 47.33% from the prior year.
• Operating Leases was $4.2 million for Q1 2026 at Ocular Therapeutix, up from $2.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.7 million in Q4 2022 to a low of $2.8 million in Q4 2025.
• Historically, Operating Leases has averaged $5.7 million across 5 years, with a median of $5.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Leases surged 57.29% in 2023, then tumbled 47.33% in 2025.
• A 5-year view of Operating Leases shows it stood at $8.7 million in 2022, then retreated by 20.74% to $6.9 million in 2023, then slipped by 22.29% to $5.3 million in 2024, then sank by 47.33% to $2.8 million in 2025, then soared by 50.27% to $4.2 million in 2026.
• The last three Operating Leases figures came in at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.